View the CAT printer-friendly / share this CAT
Title Endothelin-1 Concentration is Related to Pain Threshold in a Cancer Pain Mouse Model
Clinical Question Are higher levels of endothelin-1 related to higher levels of pain than lower levels of endothelin-1 in Oral Squamous Cell Carcinoma?
Clinical Bottom Line ET-1 concentration is a determinant of the level of pain in a cancer pain mouse model. Future treatment regimens for cancer pain directed at ET-1 receptor antagonism (ET receptor A) through customized care shows promise. (See Comments on the CAT below)
Best Evidence (you may view more info by clicking on the PubMed ID link)
PubMed ID Author / Year Patient Group Study type
(level of evidence)
#1) 17664075Pickering/2007Melanoma- 5, OSCC-5, Control-3Randomized controlled trial in the mouse
Key resultsThe mean percent difference in 50% paw withdrawal threshold for the SCC group was significantly lower than both the melanoma group and the sham group on all post-inoculation testing days. The mean percent difference in 50% paw withdrawal threshold for the melanoma groups was significantly lower than the Sham group on all post-inoculation testing days except for day 4. The correlation between tumor volume and 50% paw withdrawal threshold was assessed within the SCC and melanoma groups (Fig. 2a and b, respectively). A linear (Pearson) correlation test demonstrated a negative correlation between tumor size and pain threshold in all experimental cancer groups. However, the correlation was stronger with r = _0.726 in the melanoma group. (p < 0.0001) than in the SCC group with r = _0.351 (p = 0.0474). Treatment with ETAR antagonist, BQ123, significantly blocked OSCC pain whereas no affect was seen on melanomas that don’t secrete ET-1.
Evidence Search (("Receptors, Endothelin"[Mesh] OR "Endothelin-1"[Mesh]) AND "Mouth Neoplasms"[Mesh]) AND "Pain"[Mesh] ...view in PubMed
Comments on
The Evidence
The design was a RCT. The groups were the same at the start and the groups were treated the same. There was a greater than 80% completion rate. There was adequate follow up and there does not appear to be any competing interests.
Applicability Currently only animal research is available. Future treatment regimens for cancer pain directed at ET-1 could be utilized through customized care (especially ET receptor A).
Specialty/Discipline (Oral Medicine/Pathology/Radiology) (Oral Surgery)
Keywords Animals, Carcinoma, Squamous cell/Pathology, Cell line, Tumor, Mice, Pain/drug therapy, Pain/etiology, Receptor, Endothelin A/antagonists & inhibitors
ID# 592
Date of submission: 04/01/2010spacer Revised: 12/06/2011
E-mail adicks@livemail.uthscsa.edu
Author Jennifer Adicks
Co-author(s) e-mail
Faculty mentor/Co-author Cara Gonzales, PhD, DDS
Faculty mentor/Co-author e-mail gonzalesc5@uthscsa.edu
Basic Science Rationale
(Mechanisms that may account for and/or explain the clinical question, i.e. is the answer to the clinical question consistent with basic biological, physical and/or behavioral science principles, laws and research?)
post a rationale
None available
Comments and Evidence-Based Updates on the CAT
post a comment
by Nicholas Cox, Jack Hua, Stacye Joyner (San Antonio, TX) on 01/07/2013
A PubMed search on the endothelin-1 concentration relation to pain threshold in a cancer pain mouse model produced two more recent publications: PubMed IDs 21972258 (Viet, 2012-research supported) 21782343 (Viet, 2011-review article). Both confirmed the previous CAT.

Return to Found CATs list